The Bharat Cancer Genome Atlas (BCGA) is a monumental step for cancer research in India. IIT Madras launched this comprehensive, first-of-its-kind genomic database on World Cancer Day. It specifically covers cancers like paediatric leukaemia, colorectal, and pancreatic cancers. The database is now publicly available for researchers and clinicians both in India and globally. Ultimately, the BCGA addresses the critical gap where Indian-specific genomic data is under-represented in worldwide cancer studies. For those looking to advance their understanding of cancer genomics and targeted therapies, considering a course in Clinical Oncology is highly recommended.
Bridging the Genomic Data Gap with the Cancer Genome Atlas
India has a significant incidence of cancer, yet its patient data remains under-represented in global genomic studies. This disparity creates a major obstacle for precision oncology development in the country. Therefore, the BCGA was initiated to map the unique genetic landscape of cancers within the Indian population. This curated collection of genetic variants will facilitate several crucial clinical outcomes. For instance, it can aid in early diagnosis, help track disease progression, and effectively guide therapeutic decisions. Moreover, the absence of a comprehensive genomic architecture for local cancers previously hindered specific diagnostic kit and drug development. This database identifies cancer-specific biomarkers in India, which enables earlier and more targeted detection.
The urgent need for this resource is highlighted by the ICMR data, which indicates that one in nine people in India is likely to develop cancer in their lifetime. Furthermore, the National Cancer Registry Programme reports a concerning 12.8% annual increase in cancer incidence since 2022. Approximately 2.5 million people currently live with the disease in India. Therefore, the BCGA provides a vital foundation for a shift toward “personalized medicine,” incorporating individual genetic data into clinical decisions. Professionals keen on mastering the genetic basis of disease can explore the Postgraduate Diploma In Genomic Medicine And Health.
Project Scope and Collaborative Support
The BCGA is part of the larger Bharat Cancer Genome Grid (BCG2), which is designed as a clinician-centric national initiative. Significantly, the project received principal support of ₹56 crore from the Hyundai Motor India Foundation. This funding was allocated under their flagship ‘Hyundai Hope for Cancer’ initiative. Researchers involved in the project performed whole-genome sequencing of patient samples collected nationwide. This complex process required standardizing protocols for preserving samples in liquid nitrogen at -196 degrees Celsius. The initiative represents a major collaborative effort across multiple institutions, including Karkinos Healthcare, the KK Childs Trust Hospital, and the Institute of Child Health, Chennai. Eventually, the goal of BCG2 is to bridge the gap between large-scale data generation and its meaningful application at the patient bedside.
Beyond advancing genomic research, the partnership with Hyundai also includes a ₹3 crore fund. This amount supports cancer treatment for low-income families and facilitates the deployment of mobile medical units in underserved regions.
Frequently Asked Questions
Q1: Which specific cancers are included in the initial release of the Bharat Cancer Genome Atlas (BCGA)?
The initial release of the BCGA includes comprehensive genomic data for paediatric leukaemia, colorectal cancer, and pancreatic cancer. These are cancers where Indian-specific genomic data was critically lacking. Training related to childhood conditions, such as paediatrics, remains crucial in clinical practice.
Q2: Who is the primary funder of the Bharat Cancer Genome Atlas project?
The Bharat Cancer Genome Atlas project received principal support of ₹56 crore from the Hyundai Motor India Foundation, operating under its ‘Hyundai Hope for Cancer’ initiative.
Q3: How will the BCGA help clinicians and researchers in India?
The curated genetic variant data will help clinicians facilitate early diagnosis, track disease progression, and guide therapeutic decisions. It also provides an invaluable resource for researchers to identify cancer-specific biomarkers and develop targeted diagnostic kits and drugs tailored to the Indian population. Exploring the Oncology Speciality Courses can further equip professionals in this domain.
References
- IIT-M releases cancer genome database to identify biomarkers in India – ETHealthworld
- iitm.ac.in
- educationworld.in
- etvbharat.com
- devdiscourse.com
- newindianexpress.com
- karkinos.in
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.